|
May 6
|
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
|
|
May 3
|
Amarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Call Transcript
|
|
May 3
|
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
|
|
May 2
|
Amarin First Quarter 2024 Earnings: EPS Beats Expectations
|
|
May 1
|
Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates
|
|
May 1
|
Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript
|
|
May 1
|
Amarin Corp PLC (AMRN) Q1 2024 Earnings: Navigating Challenges with Strategic Focus
|
|
May 1
|
Amarin Reports First Quarter 2024 Business Update and Financial Results
|
|
Apr 24
|
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
|
|
Apr 22
|
Amarin Announces Results of Annual General Meeting of Shareholders
|
|
Apr 15
|
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
|
|
Apr 8
|
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
|
|
Apr 8
|
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
|
|
Apr 6
|
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
|
|
Apr 4
|
Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe
|
|
Apr 3
|
Why Amarin Stock Was Rocketing Higher on Wednesday
|
|
Apr 3
|
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
|
|
Mar 25
|
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
|
|
Mar 5
|
Amarin Full Year 2023 Earnings: Beats Expectations
|
|
Mar 2
|
Earnings Update: Amarin Corporation plc (NASDAQ:AMRN) Just Reported And Analysts Are Trimming Their Forecasts
|